OMNIlife science, a subsidary of Orthopaedic Synergy, has received the US Food and Drug Administration (FDA) approval for Apex Posterior Stabilized (PS) Knee.
The Apex PS Knee maintains the same design elements of the existing Apex Cruciate Retaining (CR) Knee but offers the post and cam system which helps to perform a posterior stabilized knee replacement.
The design allows the Apex PS Knee to have up to an additional 30 degrees of uninterrupted patella track compared to competitive posterior stabilized knee designs that require a larger bone resection.
The extra patella track reduces the chance of a problem associated with knee replacements known as patella ‘clunk’.
OMNIlife said by taking advantage of the intercondylar fossa for the location of the Apex PS Knees’ ‘box’ cut, there is 90%reduction in the bone removed compared to other PS knee designs.
Orthopaedic Synergy and OMNIlife science CEO George Cipolletti said the design of the Apex PS Knee will set a new standard in the Orthopaedic industry that will benefit both patients and surgeon.